PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsPeginterferon alfa-2a
Peginterferon alfa-2a
Pegasys (peginterferon alfa-2a) is a protein pharmaceutical. Peginterferon alfa-2a was first approved as Pegasys on 2002-06-20. It is used to treat brain neoplasms, chronic hepatitis b, chronic hepatitis c, colorectal neoplasms, and cryoglobulinemia amongst others in the USA. It has been approved in Europe to treat chronic hepatitis b and chronic hepatitis c.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
neoplasmsD009369
digestive system diseasesD004066
nervous system diseasesD009422
eye diseasesD005128
urogenital diseasesD000091642
cardiovascular diseasesD002318
hemic and lymphatic diseasesD006425
skin and connective tissue diseasesD017437
immune system diseasesD007154
Show 1 more
Trade Name
FDA
EMA
Pegasys (discontinued: Pegasys)
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Peginterferon alfa-2a
+
Ribavirin
Tradename
Proper name
Company
Number
Date
Products
Pegasys Copegus Combination Packpeginterferon alfa-2a and ribavirinRocheN-125083 DISCN2004-06-04
3 products
Hide discontinued
Peginterferon alfa-2a
Tradename
Proper name
Company
Number
Date
Products
Pegasyspeginterferon alfa-2aPharma&N-103964 RX2002-10-16
2 products
Show 1 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
pegasysBiologic Licensing Application2025-08-11
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
L: Antineoplastic and immunomodulating agents
L03: Immunostimulants
L03A: Immunostimulants
L03AB: Interferons
L03AB11: Peginterferon alfa-2a
L03AB61: Peginterferon alfa-2a, combinations
HCPCS
No data
Clinical
Clinical Trials
710 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
HepatitisD006505K75.92414110912881462
Hepatitis aD006506EFO_0007305B15211199612675419
Hepatitis cD006526B19.2201291089955390
Chronic hepatitis cD019698EFO_0004220B18.21392817848299
Chronic hepatitisD006521K73.91348374825160
Chronic hepatitis bD019694EFO_0004239B18.11340234828144
Hepatitis bD006509930234536138
Hiv infectionsD015658EFO_0000764B205201210245
InfectionsD007239EFO_000054421866232
Liver cirrhosisD008103EFO_0001422K74.0352917
Show 32 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Renal cell carcinomaD002292EFO_00003762146120
Hepatitis dD003699EFO_0007304183314
LeukemiaD007938C95284113
Bcr-abl positive chronic myelogenous leukemiaD015464EFO_00003407712
Chronic hepatitis dD01970114318
Essential thrombocythemiaD013920D47.31438
MelanomaD0085451548
Polycythemia veraD011087D451337
ThrombocytosisD013922D75.831326
Myeloid leukemiaD007951C921516
Show 15 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients819
Kaposi sarcomaD012514C4622
PsoriasisD011565EFO_0000676L4011
Hepatic insufficiencyD04855011
Plexiform neurofibromaD018318EFO_000065811
NeurofibromaD009455EFO_000062211
HemangiosarcomaD00639411
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common namePeginterferon alfa-2a
INNpeginterferon alfa-2a
Description
Interferon alpha-2 precursor (Interferon alpha-A) (LeIF A)
Classification
Protein
Drug classPEGylated compounds, covalent attachment of macrogol (polyethylene glycol) polymer
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
Identifiers
PDB
CAS-ID
RxCUI
ChEMBL IDCHEMBL1201560
ChEBI ID
PubChem CID
DrugBankDB00008
UNII IDQ46947FE7K (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 7,657 documents
View more details
Safety
Black-box Warning
Black-box warning for: Pegasys
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
65,600 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use